2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Further support for diabetes treatments for Parkinson’s
A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development of Parkinson’s in people with diabetes.
Important phase 1 trial results for LRRK2 inhibitor drug
This week the biotech company Denali Therapeutics announced the results of a phase 1 clinical trial of their LRRK2 inhibitor drug called ‘DNL151’. Their findings have interesting implications for the Parkinson’s community.
PD Avengers webinar hosted by Cure Parkinson’s: Women with Parkinson’s
Can meeting the needs of women living with Parkinson’s unlock new treatments to better manage, slow, stop or even cure Parkinson’s? Re-watch our recent webinar.
Iron and the brain
Recent studies exploring iron levels in the brains of people with Parkinson’s have shown important implications for its use as a biomarker, as well as a way of potentially assessing the progression of the condition.
iLCT provides template for drug repurposing in other conditions
The International Linked Clinical Trials programme (iLCT) is one of the largest drug repurposing initiatives in medical research. A recent review article provides an overview of the history, structure and progress of this successful programme.